T he patients' rights and cross-border care directive is widely seen as the beginning of a new era for European action in health services. 1 While cross-border care only affects a small percentage of European Union citizens, an important section of the directive provides for a series of collaborative initiatives between Member States. It is this part of the directive that is likely to be highly influential in shaping the manner future health services across the European Union. One such initiative is the establishment of European Reference Networks (ERNs).
Earlier this year, the decisions regulating the setting up and management of ERNs were adopted. 2, 3 These decisions serve to lay down the framework within which ERNs will operate. Much preparatory work has gone into the development of the framework, and there is a general expectation that ERNs will have to meet rigorous standards both to be initially approved as well as on an ongoing basis.
European citizens aspire to have knowledge about where the 'best' care for their condition exists within the European Union and increasingly expect to access such care. 4 In this sense, the establishment of ERNs appeals to a populist objective in terms of cross-border care. ERNs undoubtedly also appeal to health-care professionals involved in cutting-edge research and medical education and could place the European Union in a stronger leadership position in medical research. 5 There remain, however, several issues that need to be addressed and challenges to be overcome to ensure that this important project actually achieves its potential impact throughout the European Union.
ERNs are theoretically based on the literature surrounding volume, concentration of expertise and patient outcomes, albeit the fact that the literature does not illustrate a linear relationship between these parameters across all disciplines. 6 One of the guiding principles for the ERN initiative is that ERNs should be established only where there is clear added value at European level. This assessment will vary depending on whose yardstick is used, as added value at European level is likely to be perceived differently by Member States depending on their population size and level of economic development. As the spirit of the directive is that of enhancing cooperation between Member States, there should be sufficient flexibility and openness to allow networks to be formed where there is sufficient demand for them rather than engaging in protracted theoretical or political discussions on whether this will bring European added value.
The setting up of ERNs is likely to continue to accentuate a concentration of centres within the larger and richer European Union Member States. While this is not unexpected, the actual setting up of ERNs should serve as a stimulus for centres that initially start out as 'affiliated' to the network to develop fully particularly if they can improve access to high-quality services for an underserved geographic region of the European Union. European structural and investment funds could be usefully applied to such developments. The concept of setting up networks of centres of reference is interesting partly also because it tends to go against the market concept of competition between centres of excellence to attract patients towards mutual collaboration and support. Another innovative perspective is that while in medical sciences, excellence has usually been clinically driven and emerged through a bottom-up approach, the development of ERNs as contemplated seems to be far more centrally driven than emergent.
The sustainability of ERNs will also depend on the funding for these networks. This is possibly the most serious threat to the project, as there is presently no secure sustainable form of funding available at European level. The stringent budgetary frameworks being applied to health systems at national levels, partly due to pressure being applied through the European semester mechanism, indicate that Member States will find it difficult to spare funds for the maintenance of ERNs.
The impact on equity and health inequalities is another issue meriting close attention. The mechanisms for reimbursement under the cross-border directive pose a barrier for access to care for the following reasons. There is a good possibility that the intervention/treatment sought from a centre of reference may not be provided in the Member State's package of health-care services. Second, even if the Member State does agree to provide the authorization given the rarity or complexity of the patient's condition, difficulties arise in establishing a reimbursement price based on the principle of how much the treatment would have cost in the competent Member State. Cross-border referral to centres of reference may end up being too costly both for a Member State as well as for an individual patient.
Well-designed independent research on the impact of ERNs should be a high priority for European health services research in the coming years. Such research should not only focus on filling gaps in the literature with regards to clinical outcomes and cost effectiveness but should also determine the impact on equity for European citizens. Whether ERNs will herald a new era of care for patients with rare and complex diseases across the European Union depends on the way in which some of the issue discussed above will be tacked.
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